Renaissance Technologies (RenTech)'s MGX Position Overview
Renaissance Technologies (RenTech) (via Renaissance Technologies LLC) currently holds 742,400 shares of Metagenomi Therapeutics, Inc. (MGX) worth $883,456, representing 0.00% of the portfolio. First purchased in 2024-Q3, this short-term holding has been held for 8 quarters.
Based on 13F filings, Renaissance Technologies (RenTech) has maintained this position in MGX for several quarters, showing initial confidence in the investment. Largest addition occurred in Q4 2025, adding 461,400 shares. Largest reduction occurred in Q1 2025, reducing 54,200 shares.
Analysis based on 13F filings available since 2013 Q2
Renaissance Technologies (RenTech)'s Metagenomi Therapeutics (MGX) Holding Value Over Time
Track share changes against reported price movement
Quarterly Metagenomi Therapeutics (MGX) Trades by Renaissance Technologies (RenTech)
| Report Date | Bought/Sold (Sh.) | % Change | Qtr. End Shares | Reported Price |
|---|---|---|---|---|
| Q2 2026 | -45,500 | Reduce 5.77% | 742,400 | $1.19 |
| Q1 2026 | +159,500 | Add 25.38% | 787,900 | $1.34 |
| Q4 2025 | +461,400 | Add 276.29% | 628,400 | $1.62 |
| Q3 2025 | +48,000 | Add 40.34% | 167,000 | $2.37 |
| Q2 2025 | +19,400 | Add 19.48% | 119,000 | $1.48 |
| Q1 2025 | -54,200 | Reduce 35.24% | 99,600 | $1.36 |
| Q4 2024 | -28,300 | Reduce 15.54% | 153,800 | $3.61 |
| Q3 2024 | +182,100 | New Buy | 182,100 | $2.17 |
Renaissance Technologies (RenTech)'s Metagenomi Therapeutics Investment FAQs
Renaissance Technologies (RenTech) first purchased Metagenomi Therapeutics, Inc. (MGX) in Q3 2024, acquiring 182,100 shares, as reported in their 13F filing for that period. Note: Analysis reflects filings available since Q2 2013; earlier records may be incomplete.
Renaissance Technologies (RenTech) has held Metagenomi Therapeutics, Inc. (MGX) for 8 quarters since Q3 2024.
Renaissance Technologies (RenTech)'s largest addition to Metagenomi Therapeutics, Inc. (MGX) was in Q4 2025, adding 628,400 shares worth $1.02 M.
According to the latest 13F filing for Q2 2026, Renaissance Technologies (RenTech)'s firm, Renaissance Technologies LLC, owns 742,400 shares of Metagenomi Therapeutics, Inc. (MGX), valued at approximately $883,456.
As of the Q2 2026 filing, Metagenomi Therapeutics, Inc. (MGX) represents approximately 0.00% of Renaissance Technologies (RenTech)'s publicly disclosed stock portfolio, making it one of their key holdings.
Renaissance Technologies (RenTech)'s peak holding in Metagenomi Therapeutics, Inc. (MGX) was 787,900 shares, as reported at the end of Q1 2026.